Journal
CHEMISTRY-A EUROPEAN JOURNAL
Volume 29, Issue 5, Pages -Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/chem.202202408
Keywords
enterobactin; Gram-negative bacteria; MraY; muraymycins; siderophore-drug conjugate
Categories
Ask authors/readers for more resources
Overcoming antibiotic resistance requires the development of novel antibacterial agents that target new bacterial cell mechanisms. This study presents a new approach by conjugating a synthetic muraymycin analogue with an enterobactin derivative to enhance cellular uptake and improve antibacterial activity against Gram-negative bacteria.
Overcoming increasing antibiotic resistance requires the development of novel antibacterial agents that address new targets in bacterial cells. Naturally occurring nucleoside antibiotics (such as muraymycins) inhibit the bacterial membrane protein MraY, a clinically unexploited essential enzyme in peptidoglycan (cell wall) biosynthesis. Even though a range of synthetic muraymycin analogues has already been reported, they generally suffer from limited cellular uptake and a lack of activity against Gram-negative bacteria. We herein report an approach to overcome these hurdles: a synthetic muraymycin analogue has been conjugated to a siderophore, i. e. the enterobactin derivative Ent(KL), to increase the cellular uptake into Gram-negative bacteria. The resultant conjugate showed significantly improved antibacterial activity against an efflux-deficient E. coli strain, thus providing a proof-of-concept of this novel approach and a starting point for the future optimisation of such conjugates towards potent agents against Gram-negative pathogens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available